Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 5/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3693832 | 1.00 | PPARA (0.52) | PPARACTSSPPARGRENRAB9A | |
| SCHEMBL3385229 | 1.00 | PPARA (0.52) | PPARACTSSPPARGRENRAB9A | |
| SCHEMBL12053960 | 0.90 | PPARA (0.53) | PPARACTSSPPARGRENRAB9A | |
| SCHEMBL14003960 | 0.90 | PPARA (0.53) | PPARACTSSPPARGRENRAB9A | |
| SCHEMBL27675050 | 0.84 | PPARA (0.56) | PPARACTSSPPARGRENRAB9A | |
| SCHEMBL12053946 | 0.84 | PPARA (0.56) | PPARACTSSPPARGRENRAB9A | |
| SCHEMBL6043882 | 0.84 | MEN1 (0.52) | PPARACTSSRENMEN1KMT2A | |
| SCHEMBL6042847 | 0.84 | MEN1 (0.52) | PPARACTSSRENMEN1KMT2A | |
| SCHEMBL3327537 | 0.82 | CA1 (0.53) | CTSSRENKLK5L3MBTL1BACE1 | |
| SCHEMBL3196374 | 0.82 | PPARA (0.61) | PPARACTSSPPARGRENRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338620-B2 | Methods for the production of C-8 lactam lactone compounds | NOVARTIS AG (CH) | 2012-12-25 | — | — | US | disclosed |
| US-8338620-B2 | Methods for the production of C-8 lactam lactone compounds | NOVARTIS AG (CH) | 2012-12-25 | — | — | US | disclosed |
| US-8338620-B2 | Methods for the production of C-8 lactam lactone compounds | NOVARTIS AG (CH) | 2012-12-25 | — | — | US | disclosed |
| US-20100130749-A1 | METHODS | NODEN PHARMA DAC (IE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130749-A1 | METHODS | NODEN PHARMA DAC (IE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130749-A1 | METHODS | NODEN PHARMA DAC (IE) | 2010-05-27 | — | — | US | disclosed |
| EP-2142497-A1 | NEW METHODS | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119804-A1 | NEW METHODS | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130749-A1 | METHODS | REN, AGTR1, AGTR2 | PPARA 3714/4885CTSS 486/4885PPARG 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.